Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
GIP Arronax is a French public interest group that operates the ARRONAX cyclotron, a high-energy particle accelerator dedicated to research and production of radioisotopes for nuclear medicine. Located in Saint-Herblain, the facility focuses on developing innovative radionuclides for targeted alpha therapy and positron emission tomography (PET) imaging, such as Astatine-211 and Copper-64. The organization serves as a collaborative hub for academic researchers and industrial partners, providing high-purity isotopes and irradiation services. GIP Arronax plays a critical role in the European radiopharmaceutical supply chain, supporting the development of new diagnostic and therapeutic tools for oncology.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on GIP Arronax.